Abbott's humira has new use

LIBERTYVILLE TOWNSHIP -- Abbott Laboratories' top-selling drug, humira, won U.S. approval to treat juvenile rheumatoid arthritis. This is the sixth use for humira approved by the Food and Drug Administration, and the second this year, the Libertyville Township-based company said Friday in a statement. Juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis, affects about one in 1,000 children, according to Cincinnati Children's Hospital.